利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.037 秒)

    TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF
    3.
    发明申请
    TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF 有权
    三唑化合物，制剂方法，药物组合物及其用途

    公开(公告)号：US20090298832A1

    公开(公告)日：2009-12-03

    申请号：US12306499

    申请日：2006-08-15

    申请人： Song Li ,  Changbin Guo ,  Xiancheng Jiang ,  Junhai Xiao ,  Zhong Wu

    发明人： Song Li ,  Changbin Guo ,  Xiancheng Jiang ,  Junhai Xiao ,  Zhong Wu

    IPC分类号： A61K31/426 ,  C07D277/38 ,  C07D417/04 ,  A61P9/00 ,  A61K31/5377 ,  A61K31/496

    CPC分类号： C07D277/40 ,  C07D277/24 ,  C07D277/42 ,  C07D277/44 ,  C07D277/46 ,  C07D277/50 ,  C07D277/52

    摘要： The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

    摘要翻译： 本发明涉及用于抑制血浆PLTP活性和/或血浆CETP活性的式（I）的2,4,5-三取代噻唑化合物或其所有可能的异构体，前体药物，药学上可接受的盐，溶剂合物或水合物，其中 取代基如说明书中所定义; 制备式（I）化合物的方法; 包含式（I）化合物及其用于制备用于治疗和/或预防与哺乳动物例如动脉粥样硬化增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途的药物组合物 ，心血管疾病和外周血管疾病等

    Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof
    4.
    发明授权
    Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof 有权
    三取代噻唑化合物，制剂方法，药物组合物和医药用途

    公开(公告)号：US08053581B2

    公开(公告)日：2011-11-08

    申请号：US12306499

    申请日：2006-08-15

    申请人： Song Li ,  Changbin Guo ,  Xiancheng Jiang ,  Junhai Xiao ,  Zhong Wu

    发明人： Song Li ,  Changbin Guo ,  Xiancheng Jiang ,  Junhai Xiao ,  Zhong Wu

    IPC分类号： C07D277/44 ,  A61K31/425

    CPC分类号： C07D277/40 ,  C07D277/24 ,  C07D277/42 ,  C07D277/44 ,  C07D277/46 ,  C07D277/50 ,  C07D277/52

    摘要： The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

    摘要翻译： 本发明涉及用于抑制血浆PLTP活性和/或血浆CETP活性的式（I）的2,4,5-三取代噻唑化合物或其所有可能的异构体，前体药物，药学上可接受的盐，溶剂合物或水合物，其中 取代基如说明书中所定义; 制备式（I）化合物的方法; 包含式（I）化合物及其用于制备用于治疗和/或预防与哺乳动物例如动脉粥样硬化增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途的药物组合物 ，心血管疾病和外周血管疾病等

    Multi-layer stack adjacent to granular layer
    5.
    发明授权
    Multi-layer stack adjacent to granular layer 有权
    多层堆叠与颗粒层相邻

    公开(公告)号：US08404368B2

    公开(公告)日：2013-03-26

    申请号：US12847768

    申请日：2010-07-30

    申请人： Zhong Wu ,  Shanghsien Rou

    发明人： Zhong Wu ,  Shanghsien Rou

    IPC分类号： G11B5/66 ,  G11B5/667 ,  G11B5/673

    CPC分类号： G11B5/82 ,  G11B5/65 ,  G11B5/66

    摘要： In some embodiments, an article comprising a first magnetic recording layer, the first magnetic recording layer including a granular layer having a first magnetic anisotropy and a multi-layer stack adjacent the granular layer, the multi-layer stack comprising one or more substantially magnetic film layers alternating with one or more polarization conductor layers, wherein the multi-layer stack has a second magnetic anisotropy that is greater than the first magnetic anisotropy.

    摘要翻译： 在一些实施例中，一种包括第一磁记录层的物品，第一磁记录层包括具有第一磁各向异性的颗粒层和与颗粒层相邻的多层堆叠，所述多层堆叠包括一个或多个基本磁性膜 层与一个或多个极化导体层交替，其中多层堆叠具有大于第一磁各向异性的第二磁各向异性。

    MULTI-LAYER STACK ADJACENT TO GRANULAR LAYER
    6.
    发明申请
    MULTI-LAYER STACK ADJACENT TO GRANULAR LAYER 有权
    多层堆叠与颗粒层相邻

    公开(公告)号：US20120026627A1

    公开(公告)日：2012-02-02

    申请号：US12847768

    申请日：2010-07-30

    申请人： Zhong Wu ,  Shanghsien Rou

    发明人： Zhong Wu ,  Shanghsien Rou

    IPC分类号： G11B5/82 ,  B05D5/12

    CPC分类号： G11B5/82 ,  G11B5/65 ,  G11B5/66

    摘要： In some embodiments, an article comprising a first magnetic recording layer, the first magnetic recording layer including a granular layer having a first magnetic anisotropy and a multi-layer stack adjacent the granular layer, the multi-layer stack comprising one or more substantially magnetic film layers alternating with one or more polarization conductor layers, wherein the multi-layer stack has a second magnetic anisotropy that is greater than the first magnetic anisotropy.

    摘要翻译： 在一些实施例中，一种包括第一磁记录层的物品，第一磁记录层包括具有第一磁各向异性的颗粒层和与颗粒层相邻的多层堆叠，所述多层堆叠包括一个或多个基本磁性膜 层与一个或多个极化导体层交替，其中所述多层堆叠具有大于所述第一磁各向异性的第二磁各向异性。

    Substantially two dimensional isotropic magnetic recording medium comprising a NiAl underlayer
    8.
    发明授权
    Substantially two dimensional isotropic magnetic recording medium comprising a NiAl underlayer 有权
    基本二维各向同性磁记录介质，其包括NiAl底层

    公开(公告)号：US6110582A

    公开(公告)日：2000-08-29

    申请号：US149096

    申请日：1998-09-08

    申请人： Zhong Wu ,  Rajiv Y. Ranjan

    发明人： Zhong Wu ,  Rajiv Y. Ranjan

    IPC分类号： G11B5/73 ,  G11B5/84 ,  G11B5/66

    CPC分类号： G11B5/7325 ,  G11B5/8404 ,  Y10S428/90 ,  Y10T428/26 ,  Y10T428/265

    摘要： A high areal density magnetic recording medium exhibiting high H.sub.c, high SNR, high S* and substantially two dimensionally isotropic magnetic properties is achieved by depositing a NiAl underlayer on a NiP-plated non-magnetic metallic substrate, such as an Al alloy substrate. Embodiments include depositing a Cr layer on the NiAl underlayer. The NiAl underlayer and/or Cr layer can optionally contain an alloying element for inducing a preferred HCP crystallographic structure in the magnetic layer by lattice matching.

    摘要翻译： 通过在诸如Al合金基底的NiP镀非磁性金属基底上沉积NiAl底层，实现了表现出高Hc，高SNR，高S *和基本二维各向同性磁性能的高密度磁记录介质。 实施例包括在NiAl底层上沉积Cr层。 NiAl底层和/或Cr层可以任选地含有用于通过晶格匹配在磁性层中诱导优选HCP晶体结构的合金元素。

    6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF
    9.
    发明申请
    6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF 审中-公开
    6,8替代的纳林宁衍生物及其用途

    公开(公告)号：US20160130245A1

    公开(公告)日：2016-05-12

    申请号：US14784036

    申请日：2013-01-18

    申请人： Weiwei SU ,  Yonggang WANG ,  Zhong WU

    发明人： Weiwei Su ,  Yonggang Wang ,  Zhong Wu

    IPC分类号： C07D311/32 ,  A61K31/353

    CPC分类号： C07D311/32 ,  A61K31/352 ,  A61K31/353

    摘要： Disclosed in the present invention are a 6,8-substituted naringenin derivative as shown in formula (I): in which A6 and A8 in formula (I) are respectively selected from H, halogen, hydroxyl, an alkyl group with 1-3 carbon atoms, and a straight-chain alkenyl, alcohol group, aldehyde group, or carboxylic acid group containing 2-3 carbon atoms, obtained by modifying naringenin as lead compound, or a pharmaceutically acceptable salt thereof, a preparation method therefor and use thereof in preparation of drugs for improving the function of the respiratory system and relieving cough.

    摘要翻译： 在本发明中公开的是式（I）所示的6,8-取代的柚皮苷衍生物：其中式（I）中的A6和A8分别选自H，卤素，羟基，具有1-3个碳原子的烷基 原子以及通过改变柚皮苷作为铅化合物而获得的含有2-3个碳原子的直链烯基，醇基，醛基或羧酸基，或其药学上可接受的盐，其制备方法及其制备方法 用于改善呼吸系统功能和缓解咳嗽的药物。

    GENE EXPRESSION SIGNATURE FOR IL-6/STAT3 SIGNALING PATHWAY AND USE THEREOF
    10.
    发明申请
    GENE EXPRESSION SIGNATURE FOR IL-6/STAT3 SIGNALING PATHWAY AND USE THEREOF 审中-公开
    IL-6 / STAT3信号途径的基因表达及其用途

    公开(公告)号：US20150232926A1

    公开(公告)日：2015-08-20

    申请号：US14398532

    申请日：2013-05-03

    申请人： Zhong Wu ,  Martin Schlumpberger ,  John Dicarlo ,  Vikram Devgan ,  Yexun Wang

    发明人： Zhong Wu ,  Martin Schlumpberger ,  John Dicarlo ,  Vikram Devgan ,  Yexun Wang

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/16

    摘要： The present invention relates to a set of biomarkers, microarrays that provide for detection thereof, an expression signature comprising 16 genes or a subset thereof, and the use thereof in determining the regulation status of IL-6/STAT3 signaling pathway in a cell sample or subject, as well as compositions for the detection thereof. The regulation status of IL-6/STAT3 signaling pathway in a cell sample or subject may be assayed based on the level of expression of one or more of these genes. The methods and compositions provided herein may be used to evaluate IL-6/STAT3 pathway regulation status in a sample; classify a cell sample as having a deregulated or regulated IL-6/STAT3 signaling pathway; determine whether an agent modulates the IL-6/STAT3 signaling pathway; predict the response of a subject to an agent that modulates the IL-6/STAT3 signaling pathway; assign treatment to a subject; and/or evaluate the pharmacodynamic effects of therapies designed to regulate IL-6/STAT3 pathway signaling. Expression of the biomarkers is preferably determined by RT-PCR using SYBR Green methods, and the expression data analyzed and compared to a control sample by use of the random forest method.

    摘要翻译： 本发明涉及提供其检测的一组生物标志物，微阵列，包含16个基因或其子集的表达标签，以及其用于确定细胞样品中IL-6 / STAT3信号传导途径的调节状态或 受试者以及用于检测的组合物。 可以基于这些基因中的一种或多种的表达水平来测定细胞样品或受试者中IL-6 / STAT3信号通路的调节状态。 本文提供的方法和组合物可用于评估样品中的IL-6 / STAT3通路调节状态; 将细胞样品分类为具有去调节或调节的IL-6 / STAT3信号传导途径; 确定试剂是否调节IL-6 / STAT3信号通路; 预测受试者对调节IL-6 / STAT3信号通路的药剂的反应; 为受试者分配治疗; 和/或评估旨在调节IL-6 / STAT3通路信号传导的疗法的药效学作用。 优选通过使用SYBR Green方法的RT-PCR来确定生物标志物的表达，并且通过使用随机森林法分析表达数据并与对照样品进行比较。